Trevi Therapeutics, Inc. (NASDAQ: TRVI)

Trevi Therapeutics, Inc. (TREV), a clinical-stage biopharmaceutical company, is dedicated to the development and commercialization of Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The company's main business activities revolve around the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine, a mixed κ-opioid receptor agonist and µ-opioid receptor antagonist. Haduvio is designed to provide sustained relief from chronic cough for up to 24 hours.

Trevi Therapeutics operates in the biopharmaceutical industry, focusing on the development of innovative treatments for unmet medical needs. The company's operations span across various stages of clinical trials for Haduvio, with the aim of maximizing its commercial potential in the coming years. The company's primary products are Haduvio, which is an oral extended-release formulation of nalbuphine, and its primary customers are healthcare providers, such as pulmonologists and dermatologists, who treat patients with chronic cough and pruritus.

The company's Chronic Cough in IPF Program is focused on the development of Haduvio for the treatment of chronic cough in IPF patients. IPF is a rare, chronic, progressive lung disease characterized by scarring and thickening of lung tissue, leading to an irreversible loss of lung function and reduced life expectancy. The company believes that chronic coughing can have a debilitating physical and psychosocial burden, exacerbate concomitant respiratory disease, cause loss of sleep, and reduce mobility.

Trevi Therapeutics has conducted a Phase 2 clinical trial of Haduvio for chronic cough in IPF, which demonstrated statistically significant results for the primary efficacy endpoint of daytime cough frequency reduction. The company is currently conducting a Phase 2b CORAL trial, which is a randomized, double-blind, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio against placebo in IPF patients with chronic cough.

The company's RCC Program is focused on the development of Haduvio for the treatment of RCC, a condition characterized by a persistent cough lasting more than eight weeks, despite treatment for an underlying condition. The company has initiated a Phase 2a RIVER trial, which is a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover study evaluating the safety and efficacy of Haduvio in patients with RCC.

The company's Prurigo Nodularis Program is focused on the development of Haduvio for the treatment of prurigo nodularis, a pruritic condition characterized by chronic pruritus. The company has completed a Phase 2 clinical trial and an open-label extension study of Haduvio in patients with prurigo nodularis, which demonstrated statistically significant results for the primary efficacy endpoint of itch reduction. The company plans to conduct an additional Phase 3 clinical trial to support the submission of a new drug application to the FDA.

In terms of competition, Trevi Therapeutics faces competition from other biopharmaceutical companies that are developing therapies for the treatment of chronic cough and pruritus. However, the company believes that its unique mechanism of action and clinical data make Haduvio a promising potential therapy for the treatment of these conditions.